Alpha5-beta1 antibodies and their uses

US8399647B2 · kind B2 · utility

Assignees

• PFIZER INC. · US
• Bristol-Myers Squibb Company · US

Inventors

• Steven Bender · Oceanside, US
• Gerald F. Casperson · Ballwin, US
• Dana Dan Hu-Lowe · Encinitas, US
• Xin Jiang · Coppell, US
• Gang Li · Beijing, CN
• Michael North · San Diego, US
• Jianying Wang · San Diego, US
• Grant Raymond Wickman · San Diego, US
• Peter Brams · Sacramento, US
• Haichun Huang · Fremont, US
• Brigitte Devaux · Palo Alto, US
• Haibin Chen · Ningbo City, CN
• Dawn M. Tanamachi · Redwood City, US
• Kristopher Toy · San Jose, US
• Lan Yang · Burlingame, US
• Tim W. Sproul · Livermore, US
• Mark Yamanaka · Pleasanton, US

Key dates

• Filing date: Sep 20, 2011
• Grant date: Mar 19, 2013
• Expiry date: Sep 20, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.